EDSA

Edesa Biotech Inc., Stellar Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development of therapeutics for dermatological and gastrointestinal indications. The Company’s lead product candidate, EB01, is a novel non-steroidal anti-inflammatory molecule (sPLA2 inhibitor) for the treatment of chronic allergic contact dermatitis. The Company has its operations in the United States and in Canada.